Cargando…

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab, an anti-PD-1 antibody, in these patients. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fennell, Dean A, Ewings, Sean, Ottensmeier, Christian, Califano, Raffaele, Hanna, Gerard G, Hill, Kayleigh, Danson, Sarah, Steele, Nicola, Nye, Mavis, Johnson, Lucy, Lord, Joanne, Middleton, Calley, Szlosarek, Peter, Chan, Sam, Gaba, Aarti, Darlison, Liz, Wells-Jordan, Peter, Richards, Cathy, Poile, Charlotte, Lester, Jason F, Griffiths, Gareth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560642/ https://www.ncbi.nlm.nih.gov/pubmed/34656227 http://dx.doi.org/10.1016/S1470-2045(21)00471-X

Ejemplares similares

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
por: Fennell, Dean A., et al.
Publicado: (2018)

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial
por: Fennell, Dean A., et al.
Publicado: (2022)

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres
por: Fennell, Dean, et al.
Publicado: (2023)

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms
por: Singh, Anita, et al.
Publicado: (2022)

Standards of care in mesothelioma treatment
por: Harden, Susan V., et al.
Publicado: (2020)

Impact of COVID-19 on mesothelioma clinical nurse specialists
por: Taylor, Bethany, et al.
Publicado: (2021)

Understanding the Experiences of end of Life Care for Patients with Mesothelioma from the Perspective of Bereaved Family Caregivers in the UK: A Qualitative Analysis
por: Harrison, Madeleine, et al.
Publicado: (2022)

BTS guideline for the investigation and management of malignant pleural mesothelioma
por: Woolhouse, Ian, et al.
Publicado: (2018)

Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: An integrative systematic review
por: Harrison, Madeleine, et al.
Publicado: (2021)

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
por: Zhang, Min, et al.
Publicado: (2021)

Malignant pleural mesothelioma patients’ experience by gender: findings from a cross-sectional UK-national questionnaire
por: Senek, Michaela, et al.
Publicado: (2022)

A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic
por: Church, Matt, et al.
Publicado: (2021)

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
por: Zhang, Min, et al.
Publicado: (2021)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma
por: Kefas, Joanna, et al.
Publicado: (2022)

Impact of Covid-19 on lung cancer and mesothelioma specialist nurses: A survey of experiences and perceptions
por: Hargreaves, Sarah, et al.
Publicado: (2022)

Moral distress in mesothelioma and lung cancer nurses during the COVID-19 pandemic: insights from a UK survey
por: Hargreaves, Sarah, et al.
Publicado: (2023)

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2020)

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series
por: Hashimoto, Kentaro, et al.
Publicado: (2022)

Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
por: Karydis, Ioannis, et al.
Publicado: (2016)

Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma
por: Lim, Eric, et al.
Publicado: (2020)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
por: Dudek, Arkadiusz Z., et al.
Publicado: (2023)

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
por: Muers, Martin F, et al.
Publicado: (2008)

Precision Therapy for Mesothelioma: Feasibility and New Opportunities
por: Dulloo, Sean, et al.
Publicado: (2021)

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
por: Treasure, Tom, et al.
Publicado: (2011)

Mesothelioma: Hippo pathway as a target, lessons from COMMAND
por: Fennell, Dean A., et al.
Publicado: (2019)

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms
por: Szlosarek, Peter W., et al.
Publicado: (2020)

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023)

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023)

Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes
por: Jones, Riley G., et al.
Publicado: (2018)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Yoneda, Hiroto, et al.
Publicado: (2021)

Abdominal pain as an initial symptom of isolated ACTH deficiency induced by nivolumab in a patient with malignant mesothelioma
por: Hata, Koichi, et al.
Publicado: (2021)

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Evaluating the effect of immune cells on the outcome of patients with mesothelioma
por: Chee, Serena J, et al.
Publicado: (2017)

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
por: Harber, James, et al.
Publicado: (2021)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial
por: Gunatilake, Samal, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_51mo8ghlglsj5tdskjqcar6bf3